Brief: CHMP Recommends EU Approval Of Novo's Frehemgo
17/09/2026 15:17
BRIEF-CHMP Recommends EU Approval Of Novo's Frehemgo Sept 17 (Reuters) - Novo Nordisk A/S NOVOb.CO:
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) RECOMMENDS EU APPROVAL OF FREHEMGO (DENECIMIG), THE FIRST FACTOR VIIIA MIMETIC OFFERING MONTHLY, ONCE EVERY TWO WEEKS AND WEEKLY DOSING IN A PRE-FILLED PEN, FOR TREATMENT OF HAEMOPHILIA A
EXPECTS FREHEMGO LAUNCH IN EUROPE Q4 2026, EU-WIDE IN EARLY 2027
Source text: ID:nGNE9Bq066
Further company coverage: [NOVOb.CO]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals